← Eichor
Study identifier: NCT05829083 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

DUET Versus Standard Interface for Hypercapnic COPD Patients

Condition: COPD Exacerbation · Hypercapnia · COPD  ·  Sponsor: Larissa University Hospital

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation. The main questions the study aims to answer are: • Does the use of the asymmetric interface lead to: 1. A greater decrease in the patients' carbon dioxide 2. A greater decrease in respiratory rate and less dyspnea 3. Less need for advanced oxygen therapy measures 4. Same tolerance and comfort 5. Lower heart rate and blood pressure Participants will be asked to: Wear the asymmetric and conventional cannulas for 3 hours each with a 30 minute gap in-between. Arterial blood samples and various clinical parameters will be collected throughout the study period. Researchers will compare the effect of asymmetric versus conventional cannulas to answer the aforementioned questions.

This description comes directly from the study's public registry record.

Talk to the study team

Ioannis Pantazopoulos, Ph.D.  ·  6945661525  ·  pantazopoulosioannis@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (2)

Sotiria General HospitalAthens, GreeceRecruiting
University Hospital of LarissaLarissa, GreeceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05829083